In Swedish
Put in for the test

The research behind Alertix

Alertix’ assays are developed by a research team at The Swedish University of Agricultural Sciences (SLU) lead by Professor Staffan Eriksson.

The research is focused on deoxynucleotide, which are the building blocks of DNA, and especially on the enzyme thymidine kinase (TK1) as a biomarker of cancer diseases. It is previously known that TK1 is released into the bloodstream in case of tumor growth. There is also evidence that this can happen even in case of pre-cancerous conditions.

A scientific breakthrough occurred when Staffan Eriksson’s team developed an immunochemical method for measuring TK1 in the blood. The method, which is unique and patent pending, offer great benefits compared to previously established methods for determining TK1.

Alertix Canine

Assay for early detection, monitoring and screening of tumor diseases in dogs. The assay is available to veterinary clinics and laboratories in Sweden and Scandinavia.
Read more about Alertix Canine

Alertix Feline

Assay for early detection, monitoring and screening of tumor diseases in cats. The assay is under development.
Read more about Alertix Feline
Under utveckling

Alertix Equine

Assay for early detection, monitoring and screening of tumor diseases in horses. The assay is under development.
Under utveckling
Read more about Alertix Equine

About cancer in companion animals

Did you know that our companion animals are afflicted by cancer as often as humans? Dogs and cats share not only our living environment but also our lifestyle. Because of this they are exposed to the same risk factors for cancer. Veterinary care is getting better and better at treating cancer in companion animals. But the crucial factor of success is that the disease is detected in time.

Read more about cancer in companion animals